- Home
- DHAI vs KPRX Comparison
DHAI vs KPRX Comparison
Compare DHAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- KPRX
- Stock Information
- Founded
- DHAI 2007
- KPRX 1998
- Country
- DHAI United States
- KPRX United States
- Employees
- DHAI N/A
- KPRX N/A
- Industry
- DHAI
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DHAI
- KPRX Health Care
- Exchange
- DHAI NYSE
- KPRX Nasdaq
- Market Cap
- DHAI 10.5M
- KPRX 9.1M
- IPO Year
- DHAI N/A
- KPRX N/A
- Fundamental
- Price
- DHAI $0.25
- KPRX $2.82
- Analyst Decision
- DHAI
- KPRX Strong Buy
- Analyst Count
- DHAI 0
- KPRX 1
- Target Price
- DHAI N/A
- KPRX $10.00
- AVG Volume (30 Days)
- DHAI 6.2M
- KPRX 1.4M
- Earning Date
- DHAI 08-18-2025
- KPRX 08-08-2025
- Dividend Yield
- DHAI N/A
- KPRX N/A
- EPS Growth
- DHAI N/A
- KPRX N/A
- EPS
- DHAI N/A
- KPRX N/A
- Revenue
- DHAI $69,573,000.00
- KPRX $20,000.00
- Revenue This Year
- DHAI N/A
- KPRX N/A
- Revenue Next Year
- DHAI N/A
- KPRX N/A
- P/E Ratio
- DHAI N/A
- KPRX N/A
- Revenue Growth
- DHAI 5.40
- KPRX N/A
- 52 Week Low
- DHAI $0.12
- KPRX $2.51
- 52 Week High
- DHAI $3.67
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- DHAI 56.22
- KPRX 40.86
- Support Level
- DHAI $0.24
- KPRX $2.87
- Resistance Level
- DHAI $0.30
- KPRX $3.22
- Average True Range (ATR)
- DHAI 0.04
- KPRX 0.18
- MACD
- DHAI 0.00
- KPRX -0.03
- Stochastic Oscillator
- DHAI 46.14
- KPRX 21.20
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.